FDA's CBD Enforcement Policy Report To Congress May Have Offered More Questions Than Answers
Attorney Libby Baney manages and represents the Collaborative for CBD Science and Safety and has suggestions for additional questions the FDA should answer about CBD safety before it opens a regulatory path for its lawful use in non-drug products. FDA's recent report to Congress "left many searching for more guidance from the agency on what comes next as it does not offer any recommendations around the future of the agency’s oversight of the CBD industry," Baney says.
You may also be interested in...
FDA’s second report to Congress on oversight of CBD market includes results from studies of whether products are mislabeled or adulterated, but also indicates throughout that more data are needed on safety of hemp-derived CBD ingredients used in myriad consumer health, cosmetic and food products already available.
US cannabis research funding of $189m, growing 65% since 2016, isn’t keeping pace with demand for CBD products with sales projected to surpass $20bn by 2024, says the Collaborative for CBD Science and Safety. It urges industry to accelerate R&D and FDA to move forward with a regulatory framework.
Charlotte’s Web is strengthening its DTC lead while growing its brick-and-mortar retail business, accelerating its pet product distribution and working to close its Abacus Health acquisition announced in March. The Boulder, CO-based CBD product manufacturer posted a 1% decline in net sales for the first quarter, but expects a rapid escalation in the second half of the year.